Bernstein Harold 4

What Happened

• Harold Bernstein, President, R&D & Chief Medical Officer of Maze Therapeutics, exercised options for 30,000 shares (code M) on 2026-03-10 by paying $10.42/share (cost $312,600) and sold a total of 30,000 shares (codes S) that same day, producing aggregate proceeds of about $1,513,560 (29,652 shares at a weighted $50.45 = $1,495,807; 348 shares at a weighted $51.02 = $17,753). The filing also reports a separate conversion/derivative line for 30,000 shares at $0.00 (reported as disposed) — see footnotes for vesting details.

Key Details

• Transaction date: 2026-03-10; Form filed: 2026-03-12 (timely filing).
• Sales pricing: reported weighted averages $50.45 (range $50.00–$50.99) and $51.02 (range $51.00–$51.09).
• Exercise cost: 30,000 shares exercised at $10.42/share (total $312,600).
• Reported proceeds from sales: ≈ $1,513,560.
• Footnotes: sales were effected under a Rule 10b5-1 trading plan adopted Sept 29, 2025 (F1); weighted-average price ranges disclosed and available on request (F2, F3); option vesting schedule provided (F4).
• Shares owned after transaction: not specified in the provided filing summary.

Context

• This sequence shows an option exercise (derivative conversion) and near-immediate market sales of the resulting shares — a common pattern for covering exercise costs or taking liquidity rather than an explicit statement of sentiment. The 10b5-1 disclosure indicates at least some sales were preplanned under an approved trading plan. For full details (exact post-transaction holdings and the $0.00 derivative line), consult the complete Form 4 or contact the company’s SEC filings.